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ABSTRACT
This study focused on the effects of dietary cholestin (red yeast extract) on the toxicity of oxidized cholesterol in rats. The rats
were divided into eight groups and fed with or without supplement of 1% cholestin and 3% oxidized cholesterol in their diets for 8
weeks. It was found that cholestin could improve the body weight decrease and the glutathione (GSH) level in the liver, and increase
of liver and kidney weight to body weight ratio, and thiobarbituric acid-reactive substances (TBARS) level in the liver of rats caused
by oxidized cholesterol (P < 0.05). It also reduced the plasma content of alanine transaminase (ALT), aspartate transaminase (AST)
and alkaline phosphatase (ALP), indicating that cholestin could prevent the hepatotoxicity induced by oxidized cholesterol (P < 0.05).
In addition, cholestin possessed recovering effect and a short-term preventing effect on the toxicity of oxidized cholesterol in rats.
Taking all these data together, cholestin may play an important role in diminishing the toxic effects of oxidized cholesterol in rats.
Key words: cholestin, oxidized cholesterol, toxic effect, rats, liver function

INTRODUCTION
Red yeast rice is common used in China for centuries to enhance the color and flavor of food, as well as
a traditional medicine for digestive and vascular functions (1-4). In the late 1990s, dietary supplement companies decided to commercialize red yeast extracts because
of their ability to reduce cholesterol as efficiently as
statin drugs. It was placed on market in 2001(2,4-9).
However, in the spring of 2001, the US Food and Drug
Administration (FDA) banned the sale of dietary supplement containing red yeast extracts or xuezhikang(10),
which was found to contain lovastatin. Because lovastatin belongs to drug category, FDA made an administrative decision to remove this dietary supplement
(often sold as cholestin in earlier times) from the health
food store. Cholestin is the fermented product of rice on
which red yeast (Monascus purpureus) has been grown;
and it is a dietary staple in many Asian countries with
typical consumption ranging from 0.5 to 2 oz/person/
day(11). This product has been used as a food preservative
* Author for correspondence. Tel: +886-5-3622-889;
Fax: +886-5-3622-899; E-mail: yhyeh@mail.toko.edu.tw

for maintaining taste and color in fish and meat, and/
or as functional medicine (12). The medicinal properties of red yeast extract were described by pharmacologists of the Ming Dynasty (1368-1644) as cited by Ma et
al.(3). Increased levels of cholesterol and triglycerides are
known to be risk factors for developing coronary artery
diseases. Lipid-lowering agents that inhibit HMG coenzyme A reductase are now prominent among the drugs
of choice for treating hypercholesterolemia. It is another
effective way to control cholesterol level with diet and
food supplements (13). Cholestin also contains 2-6% fatty
acids including palmitic acid, linoleic acid, oleic acid and
stearic acid(14), some of which have been shown to have
the ability to reduce blood-lipid level in animal models
and humans (2,4,5,15-19). Indeed, diets enriched with
cholestin were effective in reducing cholesterol in high
cholesterol rabbits and rats (20-22).
Oxidized cholesterol as well as oxidized fatty acids
from food system have been a concern for diseases. A
variety of oxidized cholesterols have been detected in
processed foods such as meat products(23), commercial sweet baked foods (24) and seafoods(25). Therefore,
consumption of oxidized cholesterols is inevitable in
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our usual diet. The formation of oxidized cholesterols
was accelerated by polyunsaturated fatty acids (PUFAs)
present in lipids (26). Oxidized cholesterols have been
known to be more injurious to arterial cells than pure
cholesterol and are more directly connected to the development of atherosclerosis, coronary heart disease and
possibly carcinogenic effects (27-29).
In this study, an animal model was used to evaluate
the protection effect of dietary cholestin on liver injury
induced by oxidized cholesterol.

MATERIALS AND METHODS

malt extract broth Ι (Blakeslee’s formula) growth medium
(containing 20 g of malt extract, 20 g of glucose, and
1 g of peptone in 1 L of distilled water, pH 4.7) and incubated at 30°C on a rotary shaker at 220 rpm. Lovastatin
esterase activity was induced by the addition of lovastatin
ammonium salt (LAS) to each flask to a final concentration of 0.5 mg/mL. The culture was then allowed to incubate for another day before it was harvested.
The harvested red yeast was extracted with boiling
water at 100°C for 4 hr. The extract was then filtered
through a Bűchner funnel and freeze-dried. The dried red
yeast extract (cholestin) was stored at -20°C before use.
II. Preparation of Oxidized Cholesterol

I. Preparation of Cholestin

Cholestin is a fermented product of rice on which
red yeast (Monascus purpureus) has been grown.
Monascus purpureus strain BCRC 31498 was purchased
from the Bioresources Collection and Research Center
(Food Industry Research and Development Institute,
Taiwan, R.O.C.). The fungus was maintained on malt
extract broth (MEB) agar, containing 4 g/L yeast extract,
20 g/L malt extract, 20 g/L glucose, and 20 g/L agar (pH
7.0). Freshly inoculated cultures were incubated at 28°C
for 5 days, kept at 4°C as stock culture and then transferred to fresh medium monthly.
M. purpureus strain BCRC 31498 was grown in
liquid medium by inoculating one loop of stock culture
into a 500-mL Erlenmeyer flask containing 50 mL of

Cholesterol (99.9% purity, Wako Chemical, Osaka,
Japan) was heated at 150°C for 12 hr to produce oxidized
cholesterol(30), a peroxide value (POV) of approximate
50.2 meq/kg oil, a content of the thiobarbituric acid reactive substances (TBARS) of 1.58 mg/kg oil and a content
of the acid value (AV) of 1.74 mg/g oil. The values of
POV, AV and TBARS in the oil were determined by
AOAC method(31).
III. Animals

Male weanling Wistar rats were purchased from the
National Laboratory Animal Center (Taiwan, R.O.C.).
They were kept in air-conditioned room (23 ± 1°C,
50-60% humidity) lit for 12 hr/day (7 a.m. to 7 p.m.).

Table 1. Composition of rat diet in each group for test Cholestin and oxidized cholesterol
Diets
Ingredients

Basal diet
(%)

Cholestin diet
(%)

Oxidized cholesterol diet
(%)

Cholestin + oxidized
cholesterol diet (%)

Casein

20

20

20

20

Methionine

0.3

0.3

0.3

0.3

Cellulose

5

5

5

5

Corn oil

2

2

2

2

Cholesterol

3

3

0

0

Oxidized cholesterol

0

0

3

3

Choline

0.2

0.2

0.2

0.2

Mineral mix(a)

3.5

3.5

3.5

3.5

Vitamin mix(b)

1

1

1

1

Cholestin

0

1

0

1

Corn starch

65

64

65

64

(a) M inerals (per 100 g of diet): NaCl 7.4 g, K 2C6 H 5O7·H 2O 22 g, K 2SO 4 5.2 g, CaHPO 4 50 g, MgO 2.4 g, FeC6 H 5O7·5H 2O 0.6 g,
MnCO3 0.35 g, CuCO3 30 mg, CrK(SO 4)2·12H 2O 55 mg, CoCl 2·6H 2O 10 mg, KI 1 mg, ZnCO3 160 mg.
(b) Vitamin (per 100 g of diet): thiamine 100 mg, riboflavin 150 mg, pyridoxine HCl 100 mg, nicotinamide 1000 mg, D-panthenate 500 mg,
folic acid 50 mg, vitamine B12 0.1 mg, vitamin A 2.5 × 105 IU, vitamin E 100 mg, calciferol 2 × 104 IU, vitamin C 3.7 × 103 mg.
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Experimental protocol was approved by the Institutional
Animal Care and Use Committee of Toko University.
After acclimatizing for 2 weeks with a commercial nonpurified diet (rodent Laboratory Chow 5001, Purina Co.,
USA), 48 rats were divided into eight groups. Six rats in
each group were assigned to receive one or two of four
formulated diets during a 8 week period of one or two of
four formulated diets (Table 1). The diets were synthesized as described previously by the American Institute
of Nutrition (AIN)(32) and included: basal diet (control
diet), cholestin diet (1% cholestin in diet), oxidized
cholesterol diet (3% oxidized cholesterol) and oxidized
cholesterol + cholestin diet (3% oxidized cholesterol +
1% cholestin). The diet regimen used in each group was
as follows: Group A: rats were fed with basal diet for 8
weeks; Group B: rats were fed with cholestin diet for 8
weeks; Group C: rats were fed with oxidized cholesterol
diet for 8 weeks; Group D: rats were fed with cholestin
+ oxidized cholesterol diet for 8 weeks; Group E: rats
were fed with oxidized cholesterol diet for 1 month and
then with cholestin diet for 1 month; Group F: rats were
fed with oxidized cholesterol diet for 1 month and then
with basal diet for 1 month; Group G: rats were fed with
cholestin diet for 1 month and then with oxidized cholesterol diet for 1 month. Group H: rats were fed with basal
diet for 1 month and then with oxidized cholesterol diet
for 1 month. Water and food were freely available during
the experimental period. After feeding, all rats were
weighed. Blood samples were taken from the tail vein of
the rats at 0, 2, 4, 6 and 8 week intervals and analyzed.
The plasma of blood samples were collected by centrifugation (1,000 ×g for 15 min) and examined for alanine
transaminase (ALT), aspartate transaminase (AST) and
alkaline phosphatase (ALP) activities. On the 8 week,
liver and kidney of the rats were excised and weighed.
Ratios of liver and kidney weight to body weight were
obtained. The livers were stored at -40°C for glutathione
(GSH) and TBARS determinations.
IV. Assays of Enzymatic Activities

The plasma ALT, AST and ALP activities were
determined using enzymatic kit with Selectra Analyser
(Merck Co. Ltd., Germany).

V. Thiobarbituric Acid-reactive Substances (TBARS)
Production

Lipid peroxidation activities in the liver were
assayed by measurement of malondialdehyde (MDA),
an end-product of peroxidized fatty acids and thiobarbituric acid (TBA) reaction product. The sample of 20%
liver homogenate was mixed with 1.0 mL of 0.4% TBA
in 0.2 N HCl and 0.15 mL of 0.2% BHT in 95% ethanol.
The samples were incubated in a water-bath at 90°C for
45 min. After incubation, the TBAMDA adduct was
extracted with isobutanol. The isobutanol extract was
mixed with methanol (2: 1, v/v) prior to injection into
a high performance liquid chromatography (HPLC)
system (Hitachi) with a Model L-6200 pump (Tokyo,
Japan), and used to monitor by excitation at 515 nm and
emission at 550 nm Model L-4000 Hitachi fluorescence
detector (Tokyo, Japan)(33).
VI. Levels of Glutathione (GSH) Measurement

GSH reacts non-enzymatically with 5, 5'-dithiobis
(2-nitrobenzoic acid) (DTNB) to yield glutathione disulfide (GSSG) and 2-nitro-5-thiobenzoic acid (TNB). GSSG
is then reduced enzymatically by NADPH and glutathione reductase (GR) to regenerate GSH. Concentrations
of DTNB, NADPH and GR were chosen such that the
rate of the overall reaction is linearly proportional to the
concentration of total GSH. The rate of formation of TNB
was followed spectrophotometrically, and the assay was
calibrated using standards. If the sample reacted with
2-vinylpyridine, GSH is derivatized, and only GSSG can
be detected during subsequent assay(34).
VII. Histopathology

Liver samples were fixed with 10% formalin phosphatebuffer, dehydrated, paraffin-embedded and archived.
Sections of 2-4 μm of all zones of hepatic lobule were
cut sagittally and mounted on aminopropyltriethoxysilanecoated slides (APTS, A-3648, Sigma, USA). Following
deparaffinization in xylene, sections were rehydrated,
stained with hematoxylin and eosin (H&E) and examined
by light microscopy(35).

Table 2. The experimental diets in each group for tested cholestin and oxidized cholesterol
Weeks

Group
A

B

C

D

1-4 weeks

basal diet

cholestin
diet

oxidized cholesterol diet

5-8 weeks

basal diet

cholestin
diet

oxidized cho- Cholestin + oxidized
lesterol diet
cholesterol diet

E

F

cholestin + oxidized
oxidized
oxidized chocholesterol diet
cholesterol diet lesterol diet
cholestin diet

basal diet

G

H

cholestin diet

basal diet

oxidized
oxidized
cholesterol diet cholesterol diet
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Figure 1. Effect of oxidized cholesterol and cholestin on the body weight and the ratios of liver and kidney weight to body weight of rats. a-e:
values in the same week with different superscript are significantly different (P < 0.05). A, B, C, D, E, F, G and H mean eight groups of rats with
different experimental diets. (Table 2)

VIII. Statistical Analysis

Statistical analysis for differences among experimental rats in the groups was performed by the 2-way
analysis of variance procedure and Duncan’s new
multiple range test (36). A P value less than 0.05 was
considered statistically significant.

RESULTS
The effects of cholestin and oxidized cholesterol on

the growth of rats are shown in Figure 1. After feeding
for 8 weeks, the weight gains of group A and group B
rats were significant among all tested groups (P < 0.05),
indicating that oxidized cholesterol retarded the growth
of rats. The weights of group C rats were less than those
of group D rats (P < 0.05) suggesting that cholestin could
reduce the toxicity of oxidized cholesterol on the weights
of rats. Weights of group E rats were heavier than group
F rats, showing that cholestin had recovering effect
on the toxicity of oxidized cholesterol. However, the
weights of group G rats were not significantly different
from those of group H rats. It indicated that cholestin
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Figure 2. Effect of oxidized cholesterol and cholestin on the activities of AST, ALT and ALP in plasma of rats. a-f: values in the same week
with different superscript are significantly different (P < 0.05). A, B, C, D, E, F, G and H mean eight groups of rats with different experimental
diets. (Table 2)

had no preventing effect from the toxicity of oxidized
cholesterol on the weight of rats. The effects of cholestin
and oxidized cholesterol on the relative ratios of liver
and kidney weights to body weight in rats are shown in
Figure 1. After 8 week of feeding, the ratios of liver and
kidney weight to body weights of group C rats were more
significantly increased than those of group A, group B
and group E rats (P < 0.05). On the other hand, the ratios
of liver and kidney weight to body weight in group E

rats were not significantly different from those of group
A and group B rats. It meant that cholestin might reduce
the toxicity of oxidized cholesterol in the rats based
on the relative ratio of liver and kidney weight to body
weight of rats. The ratios of liver and kidney weight to
body weight in group E rats were significantly less than
those of group F rats (P < 0.05), indicating that cholestin
exhibited recovering effect on the toxicity of oxidized
cholesterol. Meanwhile, the ratios of liver and kidney
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Figure 3. Effect of oxidized cholesterol and cholestin on the concentration of glutathione (GSH) and level of thiobarbituric acid reactive
substances (TBARS) in the liver of rats. a-g: values in the same week with different superscript are significantly different (P < 0.05). A, B, C, D,
E, F, G and H mean eight groups of rats with different experimental diets. (Table 2)

weight to body weight in group G were not significantly different from those of group H rats. It meant
that cholestin had no preventing effect from the toxicity
of oxidized cholesterol based on the ratios of liver and
kidney weight to body weight in rats.
The effects of oxidized cholesterol and cholestin
on the activities of ALT, AST and ALP in rat plasma are
shown in Figure 2. It was found that the activities of ALT
and ALP in rat plasma of group C were the highest and
significantly higher than all tested groups (P < 0.05). The
activities of ALT, AST and ALP in rat plasma of group D
were significantly less than those of group C (P < 0.05),
indicating cholestin had reducing effect on the liver
toxicity of oxidized cholesterol. The activities of ALT,
AST and ALP in rat plasma of group E were significantly
less than those of group F (P < 0.05). This indicated that
cholestin exerted recovering effect on the hepatotoxicity
of oxidized cholesterol. Furthermore, the activities of
ALT, AST and ALP in rat plasma of group G were significantly less than those of group H (P < 0.05). However,
ALT and ALP activities in rat plasma of group G were
also less than those of group H (P < 0.05), indicating
cholestin exhibited a short-term preventing effect from
the liver toxicity of oxidized cholesterol on the activities
of ALT, AST and ALP in plasma of rats.
The effects of cholestin and oxidized cholesterol on
the concentrations of TBARS and GSH in the liver of
rats are shown in Figure 3. After feeding for 8 weeks,
the levels of TBARS in the livers of group C and group
H rats were higher than other groups (P < 0.05). It indicated that cholestin revealed reducing effect on the
toxicity of oxidized cholesterol based on the concentration of TBARS. The level of TBARS in the livers of
group E rats was less than group F, indicating cholestin
exerted recovering effect on the toxicity of oxidized
cholesterol. No difference was found between levels of

TBARS in the livers of group G and group H rats (P >
0.05), showing cholestin had no preventing effect from
the toxicity of oxidized cholesterol based on the TBARS
level. The concentration of GSH in the livers of group
B rats was the highest among all tested groups (Figure
3). It indicated that cholestin played a role in increasing
the GSH level in the liver of rats. The concentration of
GSH in the livers of group E rats was less than group
F (P < 0.05), indicating that cholestin exhibited recovering effect on the toxicity of oxidized cholesterol.
The concentration of GSH in the livers of group G rats
was higher than group H (P < 0.05), showing cholestin
revealed preventing effect from the toxicity of oxidized
cholesterol. But this functional effect was low because
the level of GSH in the liver of rats increased only
slightly. Judging from the above data, cholestin might
play an important role in reducing the toxic effect of
oxidized cholesterol in rats. Cholestin could increase the
body weight of rats and GSH level of liver in rats, and
decrease the enlargement of liver and kidney, the enzymatic activities of ALT, AST and ALP in the plasma and
TBARS level in the liver of rats. These results showed
that cholestin had good function in reducing toxicity
of oxidized cholesterol in rats when fed diet with the
supplement of oxidized cholesterol and cholestin at the
same time, or fed diet with the supplement of oxidized
cholesterol and then cholestin. Cholestin also had a
short-term preventing effect in reducing the toxicity of
oxidized cholesterol.
Histopathological changes were assessed by
observing liver sections for necrotic and swollen hepatocytes. The histological finding is shown in Figure 4.
Swollen cells showing enlargement and ruptured plasma
membrane were identified. Morphological alterations
involving all zones of hepatic lobule were observed
in group C, F, G and H treatment, revealing necrosis,
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Figure 4. Microscopic cross section of liver lobules in rats after 8
weeks (400x, H&E). Bar represents 0.01 mm. A, B, C, D, E, F, G
and H mean eight groups of rats with different experimental diets.
(Table 2)

degeneration and enlargement of the tubular or peritubular tissues.

DISCUSSION
In this study, the activities of ALT, AST and ALP
in plasma of rats were shown to be significantly affected
by oxidized cholesterol. In the clinical examination,
the increased levels of ALT, AST and ALP activities in plasma served as biomarkers for liver injury (37).
The activities of AST were significantly elevated in
rats fed with oxidized cholesterol for 8 weeks meaning
that oxidized cholesterol might injure liver function.
Cholestin significantly reduced the enzymatic activities
of ALT, AST and ALP in plasma of rats, indicating that
the liver injury by oxidized cholesterol could be ameliorated by cholestin. In the experimental period, the food
consumption of rats was found to significantly decrease
in those groups of rats fed oxidized cholesterol diet.
However, it was accompanied by adverse effects such as

nephrotoxicity and hepatotoxicity(38). The palatability of
the diet might also be affected. Therefore, the oxidized
cholesterol diet may induce liver injury and reduce
diet palatability in rats. TBARS was an end-product of
lipid peroxidation. The level of TBARS in the liver was
increased when the rats were fed with oxidized cholesterol. It means that the liver injury caused by feeding
with oxidized cholesterol was due to the induction of
the lipid peroxidation of liver cells. The level of TBARS
in the liver of rats was significantly reduced when the
rats were fed with the supplement of cholestin. These
results were the same as that reported previously (1,39,40).
Therefore, it was reasonable to assume that cholestin
may act as scavenger in reducing the production of lipid
peroxidation(41). Clinical trials using red yeast extract
in patients with hyperlipidemia (5,42), coronary heart
disease (43), and HIV-related dyslipidemia (44) as well
as in inhibitory effect of tumor promotion(45) have also
demonstrated an improvement in lipid profiles. In recent
reports, fermented red yeast rice preparation effectively
improves by its potential lipid-lowering effects (46-50).
This product possesses promising activity as a new
hypolipidemic drug launched worldwide (9). Meanwhile,
the function of GSH to protect biological organisms from
xenobiotic injuries was well known(25,51-53).
Lipid peroxidation is a chemical mechanism which
is capable of disrupting the structure and function of
the biological membranes that occurs as a result of
free radical attacking on lipids. When reactive oxygen
species (ROS) begin to accumulate, hepatic cells exhibit
a defensive mechanism by various antioxidant enzymes.
The main detoxifying systems for peroxides are catalase
and GSH(54). Catalase is an antioxidant enzyme, which
destroys H 2O2 that can form a highly reactive hydroxyl
radical in the presence of iron as a catalyst (55). By participating in the glutathione redox cycle, GSH together
with GSH-Px convert H 2O2 and lipid peroxides to nontoxic products. Reduced activity of one or more antioxidant systems due to the direct toxic effect of oxidized
cholesterol leads to increased lipid peroxidation, oxidative stress, and hepatotoxicity. In the current study,
oxidized cholesterol depleted GSH reservoir and reduced
catalase and GSH-Px activities. These results were
in harmony with other investigation(56). For example,
oxidized cholesterol induced hepatotoxicity was exacerbated by GSH depletion. In the current study, the depletion of GSH reservoir can account for the inhibition of
GSH-Px activity. In addition, high levels of peroxides
may explain catalase activity inhibition(57).
In our study, cholestin supplementation significantly mitigated oxidized cholesterol inducing oxidative
stress and hepatotoxicity. It was clearly manifested by
the improvement in all the biochemical variables determining oxidized cholesterol hepatotoxicity. In addition,
cholestin inhibited lipid peroxidation, diminished the
decrease in catalase and GSH-Px activities, and abrogated GSH depletion induced by oxidized cholesterol.
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Cholestin had been demonstrated as a direct antioxidant that scavenges or quenches oxygen free radicals, thus inhibiting lipid peroxidation, and as an indirect antioxidant that prevents the increase in membrane
permeability resulting from oxidant injury in many
tissues including liver and plasma (40). Cholestin might
stimulate S-nitrosylation of GSH producing S-nitrosoglutathione, which is approximately 100 times more
potent than the classical GSH(41). In addition, S-nitrosylation of cysteine residues from nitrosoglutathione
can inactivate caspase-3, thus preventing hepatic cell
apoptosis (58). Moreover, cholestin might lessen oxidized
cholesterol inducing oxidative injury and be capable
of lowering or slowing down oxidative stress (40). In
summary, the data presented in this paper showed that
administration of cholestin was a safe and effective way
to of lowering oxidized cholesterol toxicity.
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